Biopharmx Corp (NYSEAMERICAN:BPMX) shares fell 9.1% on Wednesday . The stock traded as low as $0.10 and last traded at $0.10. 2,550,151 shares changed hands during mid-day trading, an increase of 64% from the average session volume of 1,556,003 shares. The stock had previously closed at $0.11.
Several brokerages recently weighed in on BPMX. Maxim Group reaffirmed a “buy” rating and issued a $1.50 target price (down from $3.00) on shares of Biopharmx in a research report on Wednesday, September 13th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Biopharmx in a research report on Tuesday, September 19th.
In related news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total value of $59,278.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Stephen Morlock purchased 330,000 shares of the stock in a transaction that occurred on Friday, November 24th. The stock was bought at an average price of $0.15 per share, with a total value of $49,500.00. The disclosure for this purchase can be found here.
Biopharmx Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.